Citadel Advisors
OPTR

Citadel Advisors’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

Citadel Advisors’s Portfolio OPTR Stock Details OPTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,800
Closed -$73K – 7463
2013
Q3 		$73K Sell
5,800
-11,900
-67% -$158K ﹤0.01% 5569
2013
Q2 		$256K Buy
+17,700
New +$258K ﹤0.01% 4443

Citadel Advisors's OPTR Position: Q4 2013 in Review

Citadel Advisors sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q4 2013, closing a stake of 1,966,311 shares — an estimated $24.8M sold.

Citadel Advisors first reported a position in OPTR in Q2 2013 and held it in 2 quarters. The position peaked at $24.8M in Q3 2013. 0 funds tracked by Wall St. Rank hold OPTR as of Q4 2013.

  • Citadel Advisors reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q4 2013 after selling out during the quarter.
  • Citadel Advisors sold 1,966,311 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q4 2013, an estimated $24.8M.
  • Citadel Advisors first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 2 quarters.
  • Citadel Advisors's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $24.8M in Q3 2013.
  • 0 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q4 2013.

Based on Citadel Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.